Search clinical trials for: IBI315

Total 356 results

Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI302 in Patients With nAMD

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers

Healthy Subjects

China
M.D. Anderson Cancer Center

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Locally Advanced Angiosarcoma | Metastatic Angiosarcoma | Recurrent Angiosarcoma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Evaluation of IBI302 Injection in nAMD or DME

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

Advanced Malignant Tumors Lymphomas

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Hepatocellular Carcinoma

China
Sichuan University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Stage IV NSCLC

China
The First Affiliated Hospital of Xiamen University

Recruiting

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Colorectal Neoplasms

China
Buhai Wang
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

Cervical Cancer | Uterine Cervical Neoplasms | Cervix Cancer | Cervical Neoplasms

China
Tianjin Medical University Cancer Institute and...

Recruiting

Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer

Gastric Cancer | Perioperative | Sintilimab

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis

AS
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI351 in Healthy Subjects

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient (dMMR)/Microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer

Colorectal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

Neovascular Age-related Macular Degeneration

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Qian Wenbin

Not yet recruiting

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial

Extranodal NK/T Cell Lymphoma, Nasal Type

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI362 in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes

China
Pfizer

Withdrawn

Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis

Hemophilia A
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies

Small Cell Lung Carcinoma

China
Eden BioCell Ltd.
National Taiwan University Hospital

Terminated

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

Taiwan
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 in Participants With Type 2 Diabetes

Type 2 Diabetes

China
Guangdong Association of Clinical Trials

Unknown

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Nsclc
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
Sun Yat-sen University

Active, not recruiting

Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Advanced Microsatellite Stable Colorectal Cancer | Metastatic Microsatellite-stable Colorectal Cancer

China
Henan Cancer Hospital

Recruiting

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

Colorectal Cancer | Liver Metastasis
Tianjin Medical University Cancer Institute and...
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients (SMART)

Non Small Cell Lung Cancer

China
Chengappa, K.N. Roy, MD
Stanley Medical Research Institute; Maryland Psychiatric Research Center

Active, not recruiting

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

Schizophrenia

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

Type 2 Diabetes

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male

Healthy

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

Myeloid Tumor

China
Baocai Xing

Recruiting

Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

China
First Affiliated Hospital of Zhejiang University

Unknown

The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.

Gastric Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation

Hepatocellular Carcinoma Recurrent | Post-orthotopic Liver Transplantation

China
Tianjin Medical University Cancer Institute and...

Recruiting

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Gastric Cancer

China
Sun Yat-sen University

Recruiting

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

Obesity | Type 2 Diabetes

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Metastatic | Adenocarcinoma of Small Intestine | Appendix Carcinoma

China
Fujian Cancer Hospital

Unknown

Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens (ASGARD)

Advanced Metastatic Gastric Cancer
Peking Union Medical College Hospital

Completed

Effect of Triticale, Mung Bean and Adzuki Bean Intervention on Patients With Type 2 Diabetes

Type2 Diabetes Mellitus

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

B-Cell Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

China
Peking University

Not yet recruiting

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Peripheral T-cell Lymphoma

China
Shengyu Zhou

Unknown

Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) (HNSCC)

Head and Neck Squamous Cell Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

SCLC

China

3

Subscribe